Diabetes Dialogue: Prescribing Tirzepatide, Biosimilar Insulins, and Misdiagnosis of T1D
In this episode, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss their experiences with prescribing tirzepatide (Mounjaro) and what issues patients have encountered, the prospect of new biosimilar insulins that may be coming to the market, and the misdiagnosis of type 1 diabetes in adult patients.
When looking back, June 2022 will be remembered as a whirlwind month for the diabetes community. With Eli Lilly and Company announcing their novel dual GIP/GLP-1 receptor agonist tirzepatide (Mounjaro) is now available in US pharmacies and landmark data being presented at the first in-person American Diabetes Association (ADA) and Endocrine Society meetings since 2019, which occurred on back-to-back weekends, the month has been a celebration of historic advances in diabetes management.
With hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, recording 4 episodes at ADA 2022, the regularly scheduled June 2022 edition of Diabetes Dialogue: Therapeutics, Technology, and Real-World Perspectives tackles other topics of discussion from the rest of the month. During the episode, our hosts discuss their experiences with prescribing tirzepatide and what types of issues they have encountered, the prospect of new biosimilar insulins that may be coming to the market, and the misdiagnosis of type 1 diabetes in adult patients.
Diabetes Dialogue: Therapeutics, Technology, and Real-World Perspectives is available in an audio-only format on Spotify and Apple Podcasts.
